STAT+

Hospitals John Wilkerson

STAT Plus: Bernie Sanders bashes nonprofit hospitals over their tax breaks

Hospitals Tara Bannow

STAT Plus: Dana-Farber CEO on Mass General split: Boston needed a dedicated cancer hospital

Health Felice J. Freyer — Boston Globe

STAT Plus: A fraught question for the children of Alzheimer’s: Is it coming for us?

Health Tech Mohana Ravindranath

STAT Plus: How doctors and nurses shape Google’s AI, DEA extends telehealth flexibilities

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024

Biotech Adam Feuerstein

STAT Plus: Akero’s treatment for NASH falls short in cirrhosis study

Adam's Take Adam Feuerstein

STAT Plus: Bristol ‘take-under’ of Mirati is not so great for biotech, but company’s new cancer target has potential

Biotech Damian Garde

STAT Plus: FDA rejects Alnylam’s heart disease treatment over insufficient data

Biotech Matthew Herper

STAT Plus: Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies

Business Andrew Joseph

STAT Plus: A Q&A with the global head of Boehringer Ingelheim’s innovation unit

Pharma Matthew Herper

STAT Plus: Bristol Myers to buy cancer player Mirati for more than $4.8 billion

Biotech Elaine Chen

STAT Plus: Inflammation gets its own research center, thanks to Chan Zuckerberg Initiative

Health Angus Chen

STAT Plus: Long underappreciated, gamma-delta T cells may be key to colon cancer defense, study says

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems

First Opinion Vijay Ramakrishnan

STAT Plus: How payer-participating trials could help transform clinical research on FDA-approved drugs

Biotech Allison DeAngelis

STAT Plus: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug

Biotech Jonathan Wosen

STAT Plus: Neurocrine reports second late-stage trial success for congenital adrenal hyperplasia drug

Health Tech Mario Aguilar

STAT Plus: Telehealth claims data suggest service duplication, Roche app to evaluate MS symptom

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages

Biotech Andrew Joseph

STAT Plus: Kyowa Kirin to acquire Orchard Therapeutics, maker of gene therapy Libmeldy

Politics John Wilkerson

STAT Plus: 3 questions for the future of Biden’s cancer moonshot

Exclusive Jonathan Wosen

STAT Plus: Failed biotech gives a rare peek inside the tough breaks — and tough choices — that led to its demise

The Pharmalot View Ed Silverman

STAT Plus: Was Amgen less than forthcoming about FDA’s concerns on its cancer drug?

Health Matt Stout — Boston Globe

STAT Plus: Federal bill would keep addiction medication from triggering a child abuse investigation

Exclusive Rachel Cohrs and John Wilkerson

STAT Plus: Key Senate panel eyes action on drug shortages

Biotech Eric Boodman

STAT Plus: Consumer watchdog sues diagnostic firm EpicGenetics, alleging misleading claims about fibromyalgia test

Health Tech Lizzy Lawrence

STAT Plus: To prevent amputation in patients with severe vascular disease, a device turns veins into arteries

Pharmalot Ed Silverman

STAT Plus: FDA cites Fresenius Kabi for contamination problems that CDC linked to deadly sepsis cases